Hiide Yoshino

Yoshino, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis.

Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis.

Journal: Muscle & nerve

Published: May 02, 2025

Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02).

Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02).

Journal: Muscle & nerve

Published: October 23, 2024

Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment.

Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment.

Journal: Muscle & nerve

Published: October 17, 2024

Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis.

Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis.

Journal: Expert review of neurotherapeutics

Published: August 30, 2023

Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis.

Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis.

Journal: Clinical therapeutics

Published: June 28, 2023

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.

Journal: Muscle & nerve

Published: July 08, 2022

Cognitive and behavioral status in Japanese ALS patients: a multicenter study.

Cognitive and behavioral status in Japanese ALS patients: a multicenter study.

Journal: Journal of neurology

Published: June 22, 2019

Edaravone for the treatment of amyotrophic lateral sclerosis.

Edaravone for the treatment of amyotrophic lateral sclerosis.

Journal: Expert review of neurotherapeutics

Published: February 28, 2019

Japanese version of the ALS-FTD-Questionnaire (ALS-FTD-Q-J).

Japanese version of the ALS-FTD-Questionnaire (ALS-FTD-Q-J).

Journal: Journal of the neurological sciences

Published: January 19, 2016

Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration.

Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration.

Journal: Redox report : communications in free radical research

Published: July 21, 2015

Development of diabetes in a familial amyotrophic lateral sclerosis patient carrying the I113T SOD1 mutation. Case Report.

Development of diabetes in a familial amyotrophic lateral sclerosis patient carrying the I113T SOD1 mutation. Case Report.

Journal: Neuro endocrinology letters

Published: July 13, 2015

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: October 07, 2014

Showing 1-12 of 14

Last Updated: 09/26/2026